Hadassah

Hadassah and Pluristem Report Stem Cells Improve Outcome of Bone Marrow Transplant

Wednesday, Mar 11 2015

The Hadassah Medical Organization’s Department of Bone Marrow Transplantation and Cancer Immunotherapy and Israel’s Pluristem Therapeutics report in their joint study that mice with damaged bone marrow who received intramuscular injections of Pluristem stem cells (PLX-R18) together with a bone marrow transplant showed significantly faster recovery of blood cell production than those mice given a placebo with their bone marrow transplant.

A rapid return to normal blood cell counts is critical for patients following a bone marrow transplant because until white blood cell and platelet levels return to normal, patients cannot fight infections and are susceptible to hemorrhage. Pluristem Therapeutics, a leading developer of placenta-based cell therapy products, has also been working with Hadassah for several years using its PLX stem cells to treat bone marrow failure and acute radiation syndrome.

The Company's patented PLX cells release a cocktail of therapeutic proteins in response to inflammation, ischemia, hematological disorders, and radiation damage.

In this latest study, the mice were given lethal doses of radiation followed by either a low dose or a high dose of bone marrow cells and either PLX-R18 cells or the placebo. Evidence of more rapid recovery was found at the two earliest data collection time points of the study. Nine days after transplantation with a low dose of bone marrow cells and concurrent administration of either PLX-R18 or placebo, those treated with PLX-R18 showed statistically significant increases in numbers of platelets and granulocytes as compared to the controls.

Principal Investigator Prof. Reuven Or, Director of the Department of Bone Marrow Transplantation and Cancer Immunotherapy at Hadassah, explains: "A statistically significant increase in blood counts soon after bone marrow transplant is very meaningful. For the transplant patient, the most critical period for hematopoietic (blood cell production) recovery is in the days following the transplant. We were particularly encouraged to see that the administration of PLX-R18 cells resulted in the greatest early improvement when using a lower dose of bone marrow cells. This means we could one day potentially achieve success with lower bone marrow transplant doses, thus addressing both treatment costs and donor availability."

The study also revealed that nine days after transplantation with a high dose of bone marrow cells and concurrent administration of either PLX-R18 or placebo, those treated with PLX-R18 also had statistically significant increases in platelet levels. One week later, at 16 days after a low-dose transplantation, those treated with PLX-R18 cells had more platelets than controls, and those treated with PLX-R18 and a high dose of bone marrow had statistically significant increases in platelets, granulocyte, and total white blood cells.

In parallel with the Hadassah study, a preliminary study was conducted at Case Western Reserve University in Cleveland, Ohio, by Hillard M. Lazarus, MD, Professor of Medicine in the Department of Hematology and Oncology. This study is part of ongoing research there to test PLX-R18 for use in umbilical cord blood stem cell transplantation. Data in eight mice showed that six weeks after exposure to high doses of radiation, followed by transplantation with human umbilical cord blood cells, three out of four mice who received PLX-R18 cells survived compared to only one out of the four who received a placebo after transplant. At eight weeks after irradiation and transplantation, the mice who received PLX-R18 each had a higher percent of blood cells in their peripheral blood than the surviving control subject.

Zami Aberman, Chairman and Chief Executive Officer of Pluristem, comments: "Improving the outcomes of bone marrow and umbilical cord blood transplantation can have a significant impact on the treatment of a range of diseases, from blood cancers to immune and genetic disorders. We are happy with the data from preclinical studies of PLX-R18 in the context of transplantation and look forward to continuing our work in these indications with both Hadassah Medical Center and Case Western University."

Read more about our stem cell research

Comments

Related Stories

alt_text

Friday, Sep 23 2016

2016 Graduates from 19 Countries Celebrate Hadassah’s IMPH Program

Singing "It's a Wonderful Country" in Hebrew, wearing their native dress, the members of the 41st International Master of Public Health (IMPH) program of the Hadassah-Hebrew University Braun School of Public Health and Community Medicine celebrated their graduation.

READ MORE ›
alt_text

Monday, Sep 19 2016

Hadassah Hospital Treats Terror Victims After Stabbing Attacks

This last week has brought a burst of terror attacks.

READ MORE ›
alt_text

Thursday, Sep 15 2016

“Stunning Results” Continue with Hadassah’s Stem Cell Treatment to Reverse MS

The Hadassah Medical Center is continuing to receive positive findings with its Phase II clinical trial using its unique stem cell approach to stop the progression and reversing the disabilities of multiple sclerosis.

READ MORE ›
alt_text

Thursday, Sep 15 2016

2012 Hadassah Stage-Four Melanoma Patient Thankfully Healthy

"Doctors in Florida who pronounced me ‘soon-dead’ can't believe that I'm healthy today,” said Hadassah melanoma patient Stewart Greenberg.

READ MORE ›

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Membership Questions

membership@hadassah.org

(800) 664-5646

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Missions Department

missions@hadassah.org

(800) 237-1517

Show More